Episurf Medical (Nasdaq: EPISB) today provides updates regarding the business activity during Q1 2021, reflecting impacts from the current pandemic. When it issued its Q4 2020 report, published on February 19th, the company indicated low business volumes resulting from pandemic-related restrictions. However, the company can now report that it is experiencing double-digit growth in gross order intake in Q1 2021 compared to Q1 2020. Furthermore, the company has seen a 45% increase in the number of active customers during the quarter.

“These are challenging times, of course, but we are continuing to take the right steps in our early commercialization in Europe, and, if anything, we are progressing slightly better than expected during Q1 2021 against the headwinds of COVID-19-related restrictions in our markets. I am particularly happy about the strong growth in the number of active customers, as building a large global base of repeat customers is at the core of our strategy”, says Pål Ryfors, CEO Episurf Medical.